<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02998099</url>
  </required_header>
  <id_info>
    <org_study_id>B5201004</org_study_id>
    <nct_id>NCT02998099</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effect of Age on the Pharmacokinetics, Safety and Tolerability of IV Rivipansel.</brief_title>
  <official_title>A Phase 1, Non-randomized, Open-label, Parallel-group Single-dose Study To Estimate The Effect Of Age On The Pharmacokinetics, Safety And Tolerability Of Intravenous Rivipansel (Pf-06460031)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of age on PK, safety and tolerability of
      IV rivipansel.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">February 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma concentration-time profile from time 0 extrapolated to infinite time or area under the plasma concentration-time from time 0 to time of the last quantifiable concentration as data permit.</measure>
    <time_frame>Samples are collected pre-dose and at 0.33, 1, 3, 6, 8, 12, 16, 24, 36, 48 and 72 hours following single dose administration of IV rivipansel</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clearance (CL)</measure>
    <time_frame>Samples are collected pre-dose and at 0.33, 1, 3, 6, 8, 12, 16, 24, 36, 48 and 72 hours following single dose administration of rivipansel.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time profile from time 0 to time of last quantifiable concentration</measure>
    <time_frame>Samples are collected pre-dose and at 0.33, 1, 3, 6, 8, 12, 16, 24, 36, 48 and 72 hours following single dose administration of rivipansel.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration</measure>
    <time_frame>Samples are collected pre-dose and at 0.33, 1, 3, 6, 8, 12, 16, 24, 36, 48 and 72 hours following single dose administration of rivipansel.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean elimination half-life</measure>
    <time_frame>Samples are collected pre-dose and at 0.33, 1, 3, 6, 8, 12, 16, 24, 36, 48 and 72 hours following single dose administration of rivipansel.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution at steady state</measure>
    <time_frame>Samples are collected pre-dose and at 0.33, 1, 3, 6, 8, 12, 16, 24, 36, 48 and 72 hours following single dose administration of rivipansel.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical examination</measure>
    <time_frame>Baseline up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of adverse events</measure>
    <time_frame>Baseline up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of 12-lead electrocardiogram</measure>
    <time_frame>Baseline up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of vital signs</measure>
    <time_frame>Baseline up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of laboratory tests</measure>
    <time_frame>Baseline up to 72 hours</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Banked Biospecimen</measure>
    <time_frame>Day 0</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Aged 18-45 years</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of IV rivipansel over 20 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aged 65 and older</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of IV rivipansel over 20 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivipansel</intervention_name>
    <description>A single dose of IV rivipansel over 20 minutes.</description>
    <arm_group_label>Aged 18-45 years</arm_group_label>
    <arm_group_label>Aged 65 and older</arm_group_label>
    <other_name>GMI-1070</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy female subjects of non-childbearing potential or healthy male subjects who are
             between the ages of 18-45 years or 65 years of age or older.

          -  Body mass index (BMI) of 17.5 to 40 kg/m2

        Exclusion Criteria:

          -  Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
             allergic disease (including drug allergies, but excluding untreated, asymptomatic,
             seasonal allergies at the time of dosing).

          -  Pregnant females; breastfeeding female subjects; male subjects with partners currently
             pregnant

          -  Treatment with another investigational drug within 30 days or 5 half-lives preceding
             the dose of study medication

          -  Blood donation within 60 days prior to dosing.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Orlando Clinical Research Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B5201004&amp;StudyName=A+Phase+1%2C+Non-randomized%2C+Open-label%2C+Parallel-group+Single-dose+Study+To+Evaluate+The+Effect+Of+Age+And+Gender+On+The+Pharmacokinetics+Of+Intravenous+Rivipansel+%28pf-06460031%29</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B5201004&amp;StudyName=A+Phase+1%2C+Non-randomized%2C+Open-label%2C+Parallel-group+Single-dose+Study+To+Estimate+The+Effect+Of+Age+On+The+Pharmacokinetics%2C+Safety+And+Tolerability+Of+Intravenous+Rivipansel+%28pf-06460031%29</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 16, 2016</study_first_submitted>
  <study_first_submitted_qc>December 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 20, 2016</study_first_posted>
  <last_update_submitted>March 27, 2018</last_update_submitted>
  <last_update_submitted_qc>March 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy Volunteers</keyword>
  <keyword>Rivipansel</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

